A Study of KC1036 in Patients with Advanced Solid Tumors
- Registration Number
- NCT04387916
- Lead Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
- Brief Summary
The purpose of this study is to evaluate the safety，tolerability, pharmacokinetics, and preliminary efficacy of KC1036 in participants with advanced recurrent or metastatic solid tumors. The trial will be divided into three parts: dose-escalation phase, dose-expansion phase, RP2D-extension phase.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 207
- Histologically or cytologically confirmed recurrent or metastatic solid tumors;
- Patients who have failed standard or conventional treatment, Including chemotherapy, targeted therapy, immunotherapy:
Documented disease progression after, or refractory to, or intolerant of prior standard or established therapy known to provide clinical benefit for their condition; or documented disease progression within 24 weeks after prior adjuvant/neoadjuvant therapy;
- At least one measurable lesion (by RECIST 1.1);
- Eastern Cooperative Oncology Group performance status score of 0 or 1;
- Life expectancy > 12 weeks;
- Patients should participate in the study voluntarily and sign informed consent.
- Untreated brain metastases or symptoms of brain metastases cannot be controlled more than 4 weeks;
- Other kinds of malignancies;
- Hematologic, renal, and hepatic function abnormities;
- Risk of bleeding;
- Gastrointestinal abnormalitiest;
- Cardiovascular and cerebrovascular diseases;
- Prior anti-tumor therapies with chemotherapy, radiotherapy, hormonotherapy, biotherapy, immunotherapy, operation within 4 weeks of enrollment;
- Presence of unresolved toxicities from prior anti-tumor therapy, defined as having not resolved to NCI CTCAE V5.0 grade 0 or 1 with the exception of alopecia;
- Involved in other clinical trials within 4 weeks of enrollment;
- Major surgical procedure, open biopsy, or significant traumatic injury 4 weeks days of enrollment;
- History of organ allograft;
- Need immunosuppressive agents or systemic or absorbable topical hormone therapy for immunosuppression;
- Uncontrolled ongoing or active infection;
- Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy;
- Pregnant or lactating women or those who do not take contraceptives, including men;
- Suffering from mental and neurological diseases;
- Any other metabolic dysfunction, abnormal physical examination findings, or clinical laboratory findings;
- Inability to comply with protocol required procedures.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description KC1036 KC1036 Patients take a single dose of KC1036 for the pharmacokinetic study, then off for 5 days before the first cycle begins. In the subsequent treatment cycles, KC1036 are given orally once daily, 21 days as a cycle.
- Primary Outcome Measures
Name Time Method Maximum tolerated dose (MTD) First 4 weeks after initial administration of KC1036 MTD will be defined as the maximum dose level at which no more than 1 of 3 participants experience a dose-limiting toxicity (DLT) within the first 4 weeks of multiple dosing.
Adverse events (AEs) From enrollment up to 30 days after last dose Incidence of treatment-related AEs
- Secondary Outcome Measures
Name Time Method Pharmacokinetics (PK) profile: Tmax First 4 weeks after initial administration of KC1036 Time to reach the maximum plasma concentration
Objective Response Rate (ORR) Every 6 weeks for the duration of study participation; estimated to be 12 months Overall response rate (ORR) was defined as the percentage of participants with a best overall complete response (CR) or partial response (PR) per RECIST 1.1.
Duration of Response (DOR) Every 6 weeks for the duration of study participation; estimated to be 12 months Duration of response (DOR) was defined as the time from first documented response (partial response (PR) or complete response (CR)) to the date of first documented disease progression (PD) or death due to any cause, among patients with a confirmed PR or CR per RECIST 1.1.
Pharmacokinetics (PK) profile: Cmax First 4 weeks after initial administration of KC1036 Peak Plasma Concentration
Disease Control Rate (DCR) Every 6 weeks for the duration of study participation; estimated to be 12 months Disease Control Rate (DCR) was defined as the percentage of participants with a best overall complete response (CR), partial response (PR), or stable disease (SD) per RECIST 1.1.
Overall Survival (OS) From the first medication to death due to any cause; estimated to be the subject's death, loss to follow-up, or end of the study] Overall Survival (OS) was defined as the time from the start date of study drug to the date of death due to any cause.
Pharmacokinetics (PK) profile: T1/2 First 4 weeks after initial administration of KC1036 Terminal half-life
Pharmacokinetics (PK) profile: AUC0-t and AUC0-∞ First 4 weeks after initial administration of KC1036 Area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration, or Area under the single-dose plasma concentration-time curve from Hour 0 to infinity
Progression-free survival (PFS) Every 6 weeks for the duration of study participation; estimated to be 12 months Progression-free survival (PFS) was defined as the time from the start date of study drug to the date of the first radiologically documented progressive disease (PD) per RECIST 1.1 or death due to any cause.
Trial Locations
- Locations (3)
ChongQing University Cancer Hospital
🇨🇳ChongQing, Chongqing, China
The First Affiliated Hospital of Hainan Medical University
🇨🇳Haikou, Hainan, China
West China Hospital
🇨🇳Chengdu, Sichuan, China